IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease

• Status: Withdrawn
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: All

Summary

To explore the efficacy of Ivabradine for the treatment of microalbuminuria in patients with type 2 diabetes and coronary heart disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Criteria

Inclusion Criteria:

• 1. Type 2 diabetes and coronary heart disease;

• 2. Urinary albumin excretion: 30-500mg/24h;

• 3. Sinus rhythm, and resting heart rate ≥ 70bpm;

Exclusion Criteria:

• 1. Renal dysfunction defined as eGFR < 30ml/min/1.73m^2;

• 2. Atrial flutter, and atrial fibrillation;

• 3. Resting heart rate < 70bpm;

• 4. Combined with non-dihydropyridine CCB;

• 5. UAE<30mg/24h, or > 500mg/24h;

• 6. Acute heart failure;

• 7. Low blood pressure (BP<90/50mmHg);

• 8. Acute myocardial infarction (<14 days);